Hepatitis C

Associated with considerable mortality and morbidity, hepatitis C virus (HCV) affects around 70 million people worldwide causing chronic, progressive liver disease, cirrhosis and liver cancer. More than 500,000 people die from HCV-related liver diseases each year.

Many people infected with hepatitis C are unaware of their infection status leading to delayed diagnosis and people missing out on highly effective curative treatment. Currently there is no vaccine to prevent infection.

Babies born to HCV infected mothers are at risk of contracting the virus and it is also transmitted through the blood of an infected person.

Eliminating hepatitis in Australia

An estimated 180,000 Australians live with chronic hepatitis C resulting in more than 600 deaths from liver cancer and liver failure each year, making it one of Australia’s major public health issues. Highly effective curative treatments called direct-acting antivirals (DAAs) became available in Australia in March 2016.

Over 50,000 Australians are estimated to have been cured with these new treatments. However much work needs to be done if Australia is to stop new infections and deaths due to hepatitis C.

The World Health Organization set global targets to eliminate hepatitis C as a public health threat including an 80 per cent reduction of hepatitis C-reduction in new hepatitis C infections and a 65 per cent related deaths by 2030 compared with 2010.


Donate today!

Use my gift where the need is greatest

Hepatitis C: Policy Briefs

Read plain language versions of our reports, great for policymakers and community organisations.

Current Projects

  • ACCESS: STI and BBV surveillance system

  • co-EC Study: Eliminating hepatitis C/HIV coinfection

  • CREIDU: Centre for Research Excellence into Injecting Drug Use

  • CT2 Study: Community-based Testing and Treatment for Hepatitis C

  • DARE C: ATAHC II Substudy

  • Decision science using Optima

  • Development of a universal prophylactic vaccine for Hepatitis C

  • EC Partnership: Eliminate Hepatitis C Partnership

  • Eliminate Hepatitis C Australia Partnership: EC Australia

  • HCV Elimination Modelling

  • Hepatitis C and injecting networks

  • Hepatitis C brief reports

  • HepSeeVax: Proof-of-concept study of an HCV vaccine candidate

  • Methods for improved sensitivity of lateral flow tests

  • Natural history and response to treatment recent hepatitis C virus infection among a cluster of HCV genotype-1b infected individuals

  • Social Networks and the Hepatitis C Virus

  • SuperMIX: The Melbourne Injecting Drug User Cohort Study

  • The Australian Trial in Acute Hepatitis C (ATAHC)

  • The impact of viral infections on immune ageing

  • The International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)

  • The PharmEC REACH study

  • Understanding how HCV evades the immune system

  • Understanding the correlates of protection for hepaciviruses

  • What drives hepatitis C reinfection?

Past Projects

  • ALT point-of-care diagnostic to detect liver disease

  • EC Australia: The vital missing link to eliminating hepatitis C

  • PATH Cohort Study